The PARI LC PLUS and the PRONEB Ultra are the most frequently used compressor-based nebulizer system for new nebulized medications in clinical development.
About Perforomist Inhalation Solution Indication
Perforomist Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.
Important Safety Information
Perforomist Inhalation Solution belongs to a class of medications known as long-acting beta2-adrenergic agonists (LABAs). LABAs may increase the risk of asthma-related death. Data from a large placebo-controlled US study comparing the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a LABA), the active ingredient in Perforomist Inhalation Solution.
Perforomist Inhalation Solution should not be used in patients with acutely deteriorating COPD or to treat acute symptoms. Acute symptoms should be treated with fast-acting rescue inhalers. Perforomist Inhalation Solution should not be used with other medications containing LABAs. Do not use more than one nebule twice daily. Perforomist Inhalation Solution should be used with caution in patients with cardiovascular disorders. Perforomist Inhalation Solution is not a substitute for inhaled or oral corticosteroids. The safety and efficacy of Perforomist Inhalation Solution in asthma has not been established.
In COPD clinical trials, the most common adverse events reported with
Perforomist Inhalation Solution were diarrhea, nausea, nasopharyngitis, dry
mouth, vomiting, dizziness, and insomnia. Please see full Prescribing
Information, including Boxed Warning, at http://www.perf
|SOURCE PARI Respiratory Equipment, Inc.|
Copyright©2007 PR Newswire.
All rights reserved